4,369 results on '"Perkovic A"'
Search Results
152. Serum catestatin levels in patients with rheumatoid arthritis
153. Community participation in coastal and marine research and monitoring in Inuit Nunangat: a scoping literature review
154. Accelerated aging in people experiencing homelessness: A rapid review of frailty prevalence and determinants
155. National health policies and strategies for addressing chronic kidney disease: Data from the International Society of Nephrology Global Kidney Health Atlas.
156. taVNS and evoked pupil dilation: a parametric study in humans
157. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop
158. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.
159. Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology
160. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
161. Serum catestatin levels in patients with rheumatoid arthritis
162. Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial
163. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
164. Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials
165. #456 Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study
166. Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials
167. Antibiotics Prescribing Pattern and Quality of Prescribing in Croatian Dental Practices—5-Year National Study
168. The efficacy and safety of reduced-dose oral methylprednisolone in high-risk IgA nephropathy
169. WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY
170. WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
171. WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
172. WCN24-1001 EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY
173. WCN24-2313 LONG-TERM SAFETY OF HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS
174. The Stretch Factor of Hexagon-Delaunay Triangulations.
175. Identifying causal effects in maximally oriented partially directed acyclic graphs.
176. S-MODE: The Sub-Mesoscale Ocean Dynamics Experiment.
177. Meeting Challenges in IoT: Sensing, Energy Efficiency, and the Implementation
178. Alcohol-related phenotypes and platelet serotonin concentration
179. Further investigation of harmicines as novel antiplasmodial agents: Synthesis, structure-activity relationship and insight into the mechanism of action
180. Differences in the behaviour of trace and rare-earth elements in oxidizing and reducing soil environments: Case study of Terra Rossa soils and Cretaceous palaeosols from the Istrian peninsula, Croatia
181. Children with cavernous malformations of the central nervous system
182. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program
183. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
184. Exploring decision processes behind food choices : an eye tracking approach
185. Complete Graphical Characterization and Construction of Adjustment Sets in Markov Equivalence Classes of Ancestral Graphs
186. Degree Four Plane Spanners: Simpler and Better
187. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
188. Effect of sewage sludge derived compost or biochar amendment on the phytoaccumulation of potentially toxic elements and radionuclides by Chinese cabbage
189. Smart monitoring technologies for personal thermal comfort: A review
190. Plasma Brain-Derived Neurotrophic Factor Levels in First-Episode and Recurrent Major Depression and before and after Bright Light Therapy in Treatment-Resistant Depression
191. Doppler Indices of the Uterine, Umbilical and Fetal Middle Cerebral Artery in Diabetic versus Non-Diabetic Pregnancy: Systematic Review and Meta-Analysis
192. Purely kinetic k-essence description of [formula omitted] barotropic fluid models
193. Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis
194. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
195. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
196. Closing the gap between evidence and practice in chronic kidney disease
197. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data
198. Depression: Biological markers and treatment
199. Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients
200. The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.